Imlifidase denied as non-formulary by Aetna?

Aetna's specific coverage criteria for imlifidase are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Imlifidase as Non-Formulary

Imlifidase is a highly specialized biologic agent used in a narrow and specific transplant-preparatory context. Most commercial health plan formularies are structured around maintenance therapies prescribed in outpatient pharmacy settings. Because imlifidase is typically administered in an inpatient or outpatient surgical/transplant facility setting immediately before kidney transplantation, it may be processed under the medical benefit rather than the pharmacy benefit — and if it appears on neither the pharmacy formulary nor Aetna's medical-benefit covered-drugs list, a non-formulary denial results.

This type of denial is frequently resolvable through a formulary exception or by redirecting the claim to the correct benefit category.

## Your Federal Appeal Rights

• Internal appeal and formulary exception: ACA §2719 and ERISA §503 require Aetna to provide a formulary exception process. You may request a formulary exception on medical-necessity grounds — specifically that there is no formulary alternative that provides the same clinical function. Submit within the deadline on the denial notice.
• External review: If the exception request is internally denied, independent external review is available within approximately four months of the final internal adverse determination.
• Expedited option: Transplant urgency typically qualifies for expedited processing; request this explicitly and document clinical urgency.

## What to Gather Before You File

1. Determine the correct benefit category: Before filing an appeal, confirm with the transplant center's billing team and Aetna whether imlifidase should be billed under the pharmacy benefit or the medical benefit (typically as a facility-administered drug under a J-code or similar). A claim submitted to the wrong benefit category is often the root cause of a non-formulary denial. 2. Confirmation that no formulary alternative exists: Aetna's formulary exception standard requires showing that no covered alternative provides the same benefit. The transplant team's letter should state that no other covered agent performs rapid IgG cleavage in preparation for transplantation. 3. FDA-approved prescribing information: Establishes the specific mechanism and indication, supporting the argument that no substitute exists. 4. Transplant team medical-necessity letter: Explains why imlifidase is the only appropriate agent for this patient at this point in the transplant process and why the transplant cannot safely proceed without it. 5. Transplant facility billing and clinical records: Confirms the care setting and supports correct claim routing under the medical benefit.

## Criteria-Mapping Structure

| Appeal Argument | Your Documentation | Source | |---|---|---| | No formulary therapeutic alternative | Transplant team confirmation + FDA label | Letter + prescribing info | | Drug administered under medical benefit, not pharmacy | Facility administration records + billing guidance | Transplant center billing team | | Medical necessity for this patient | Sensitization records + team letter | Clinical records | | FDA-approved for this use | Label indication language | FDA prescribing information |

Addressing the correct-benefit-category question first often resolves non-formulary denials for facility-administered specialty drugs without requiring a full formulary exception process.